Single oral doses of 10 or 100 mg/kg reduced plasma and brain Aβ40 throughout the 24 h observation interval in female rats. At 1 mg/kg, plasma Aβ increased and brain Aβ40 lowering lasted 8 h. The low-dose response limits a simple assumption that all exposures lower every Aβ compartment. [2]
In 5.5-month-old Tg2576 mice, a 1 mg/kg dose improved Y-maze alternation acutely, but the benefit was absent after 8 days. In 3-month-old Tg2576 mice, 10 mg/kg daily impaired alternation on day 8, with no significant acute effect. Hippocampal β-CTF increased; its causal role in the behavioral changes remains unproven. [3]
Single-dose plasma and brain Aβ40 time course in rats
Animal study · Female Sprague-Dawley rats; n = 3 animals per time point [2]
Oral avagacestat lowered brain and plasma Aβ40 at higher doses. At 1 mg/kg, plasma Aβ increased while brain Aβ40 lowering was transient. These are biomarker outcomes, not evidence of cognitive benefit.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Single administration
- Treatment course
- 24 h pharmacodynamic time course after one dose
- Vehicle
- 99% PEG-400, 1% Tween-80; oral gavage at 4 mL/kg in SI rat protocol
- Low-dose avagacestat
- Model: Female Sprague-Dawley rats; n = 3 animals per time point
- Reported limits: No exact outcome means estimated from plotted bars/curves.
- Avagacestat 10 mg/kg
- Model: Female Sprague-Dawley rats; n = 3 animals per time point
- Reported limits: No exact outcome means estimated from plotted bars/curves.
- Avagacestat 100 mg/kg
- Model: Female Sprague-Dawley rats; n = 3 animals per time point
- Reported limits: No exact outcome means estimated from plotted bars/curves.
Methods and source locations
Compound reported in the paper: Avagacestat (BMS-708163); Compound label in the paper: 4
Evidence for the reported research compound; no verification of an Adooq lot or equivalence of formulations.
Main rat pharmacodynamic paragraph; Figure 2A,B and caption; SI Rat Studies, In life, Brain Abeta40 assay and Plasma Abeta40 assay; SI Aβ Assay In Vivo Samples/validation
Plasma and brain Aβ40 relative to vehicle: Antibody immunoassays; exact point estimates not transcribed from curves. — Figure 2A,B, caption and immediately preceding paragraph; SI rat assays/validation
Low-dose avagacestat · Main rat pharmacodynamic paragraph; Figure 2A,B and caption; SI Rat Studies, In life, Brain Abeta40 assay and Plasma Abeta40 assay; SI Aβ Assay In Vivo Samples/validation
Avagacestat 10 mg/kg · Main rat pharmacodynamic paragraph; Figure 2A,B and caption; SI Rat Studies, In life, Brain Abeta40 assay and Plasma Abeta40 assay; SI Aβ Assay In Vivo Samples/validation
Avagacestat 100 mg/kg · Main rat pharmacodynamic paragraph; Figure 2A,B and caption; SI Rat Studies, In life, Brain Abeta40 assay and Plasma Abeta40 assay; SI Aβ Assay In Vivo Samples/validation
Acute benefit did not persist after repeated dosing in older Tg2576 mice
Animal study · Female 5.5-month-old Tg2576 mice expressing human APP695 Swedish mutant; age-matched nontransgenic controls; n = 7 or 8 per group [3]
A 1 mg/kg acute dose improved Y-maze alternation, but this benefit was absent on day 8. Hippocampal β-CTF increased without measurable Aβ40/Aβ42 lowering up to 10 mg/kg.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Once daily
- Treatment course
- 8 days; Y-maze tested 3 h after dosing on days 1 and 8
- Vehicle
- 0.5% methyl cellulose
- Avagacestat dose series
- Model: Female 5.5-month-old Tg2576 mice expressing human APP695 Swedish mutant; age-matched nontransgenic controls; n = 7 or 8 per group
- Reported limits: No exact outcome means estimated from plotted bars/curves.
Methods and source locations
Compound reported in the paper: Avagacestat (BMS-708163); Compound label in the paper: BMS-708163
Evidence for the reported research compound; no verification of an Adooq lot or equivalence of formulations.
Results Experiment 1; Figure 3A,B and caption; Methods: Drugs, Animals, Y-maze test, Quantitation of hippocampal Aβ and β-CTF levels, Statistical analysis
Y-maze spontaneous alternation: Mean ± SEM, n = 7 or 8. Dunnett multiple-comparison test against vehicle; WT/Tg comparisons use Student t test. — Results Experiment 1; Figure 3A,B and caption; Methods Y-maze/Statistical analysis
Hippocampal Aβ40, Aβ42 and β-CTF: Measured after Y-maze; association does not demonstrate β-CTF-mediated causation. — Results Experiment 1; Figure 3A,B and caption; Methods Quantitation of hippocampal Aβ and β-CTF levels
Avagacestat dose series · Results Experiment 1; Figure 3A,B and caption; Methods: Drugs, Animals, Y-maze test, Quantitation of hippocampal Aβ and β-CTF levels, Statistical analysis
Repeated dosing impaired Y-maze performance in younger Tg2576 mice
Animal study · Female 3-month-old Tg2576 mice expressing human APP695 Swedish mutant; age-matched nontransgenic controls; n = 7 or 8 per group [3]
Avagacestat did not significantly alter alternation acutely but reduced it after 8 days at 10 mg/kg. Increased hippocampal β-CTF accompanied the response; causation was not established.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Once daily
- Treatment course
- 8 days; Y-maze tested 3 h after dosing on days 1 and 8
- Vehicle
- 0.5% methyl cellulose
- Avagacestat dose series
- Model: Female 3-month-old Tg2576 mice expressing human APP695 Swedish mutant; age-matched nontransgenic controls; n = 7 or 8 per group
- Reported limits: No exact outcome means estimated from plotted bars/curves.
Methods and source locations
Compound reported in the paper: Avagacestat (BMS-708163); Compound label in the paper: BMS-708163
Evidence for the reported research compound; no verification of an Adooq lot or equivalence of formulations.
Results Experiment 3; Figure 5A,B and caption; Methods: Drugs, Animals, Y-maze test, Quantitation of hippocampal Aβ and β-CTF levels, Statistical analysis
Y-maze spontaneous alternation: Mean ± SEM, n = 7 or 8. Dunnett multiple-comparison test against vehicle; WT/Tg comparisons use Student t test. — Results Experiment 3; Figure 5A,B and caption; Methods Y-maze/Statistical analysis
Hippocampal Aβ40, Aβ42 and β-CTF: Measured after Y-maze; association does not demonstrate β-CTF-mediated causation. — Results Experiment 3; Figure 5A,B and caption; Methods Quantitation of hippocampal Aβ and β-CTF levels
Avagacestat dose series · Results Experiment 3; Figure 5A,B and caption; Methods: Drugs, Animals, Y-maze test, Quantitation of hippocampal Aβ and β-CTF levels, Statistical analysis